Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling

The critical role of EGF-β-catenin signaling in the epithelial-mesenchymal transition in human glioblastoma

(2017) Xingqiang Wang et al.   OncoTargets and Therapy

Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

(2015) Min Hye Jang et al.   HUMAN PATHOLOGY

β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells

(2015) Jinhua Xu et al.   PLoS One

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

(2014) Elsa Dalmau et al.   BREAST

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

Wnt signaling in triple negative breast cancer is associated with metastasis

(2013) Nandini Dey et al.   BMC CANCER

Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies

(2013) Valentina Guarneri et al.   DRUGS

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

(2012) L. Malorni et al.   BREAST CANCER RESEARCH AND TREATMENT

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Expression of Wnt3 Activates Wnt/ -Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells

(2012) Y. Wu et al.   MOLECULAR CANCER RESEARCH

Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells

(2012) Renyue Bao et al.   PLoS One

Wnt Signaling in Cancer

(2012) P. Polakis   Cold Spring Harbor Perspectives in Biology

Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome

(2010) Andrey I. Khramtsov et al.   AMERICAN JOURNAL OF PATHOLOGY

A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer

(2010) Jenifer R. Prosperi et al.   CURRENT DRUG TARGETS

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

(2010) Felipe C Geyer et al.   MODERN PATHOLOGY

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

(2009) Shih-Min A. Huang et al.   NATURE

Wnt Signaling in Angiogenesis

(2008) Nancy Parmalee et al.   CURRENT DRUG TARGETS

Down-regulation of osteopontin attenuates breast tumour progressionin vivo

(2008) Goutam Chakraborty et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE